Page 78 - Strategies for non-invasive managementof high-grade cervical intraepithelial neoplasia - prognostic biomarkers and immunotherapy Margot Maria Koeneman
P. 78

Chapter 3
15. Eiguchi K, Tatti S, Alonio LV, Gonzalez JV, Leiros GJ, Fleider L, et al. Association of DRB1 and DQB1 HLA class II polymorphisms in high-grade and neoplastic cervical lesions of women from Argentina. J Low Genit Tract Dis. 2008;12(4):262-8.
16. Heusinkveld M, Welters MJ, van Poelgeest MI, van der Hulst JM, Melief CJ, Fleuren GJ, et al. The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. Int J Cancer. 2011;128(2):379- 89.
17. Sastre-Garau X, Loste MN, Vincent-Salomon A, Favre M, Mouret E, de la Rochefordiere A, et al. Decreased frequency of HLA-DRB1 13 alleles in Frenchwomen with HPV-positive carcinoma of the cervix. Int J Cancer. 1996;69(3):159-64.
18. Odunsi K, Ganesan T. Motif analysis of HLA class II molecules that determine the HPV associated risk of cervical carcinogenesis. Int J Mol Med. 2001;8(4):405-12.
19. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat Genet. 1994;6(2):157-62.
20. Madeleine MM, Brumback B, Cushing-Haugen KL, Schwartz SM, Daling JR, Smith AG, et al. Human leukocyte antigen class II and cervical cancer risk: a population-based study. J Infect Dis. 2002;186(11):1565-74.
21. Beskow AH, Josefsson AM, Gyllensten UB. HLA class II alleles associated with infection by HPV16 in cervical cancer in situ. Int J Cancer. 2001;93(6):817-22.
76


























































































   76   77   78   79   80